Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) announced the appointment of veteran pharmaceutical executive Dr. Keith M. Fournier to its Board of Directors. Dr. Fournier brings over 20 years of global drug development, regulatory strategy and portfolio leadership experience from roles at AbbVie, Merck KGaA’s EMD Serono, AstraZeneca’s MedImmune and Abivax.
He has led regulatory and cross-functional strategies across major programs, including VENCLEXTA and HUMIRA, and currently serves as Senior Vice President, Head of Regulatory Affairs at Abivax. According to NetraMark, his expertise in regulatory decision-making and clinical development is expected to support the Company’s AI-driven clinical trial analytics strategy and its engagement with pharmaceutical and biotechnology partners.
NetraMark (OTCQB: AINMF) will participate in the H.C. Wainwright 28th Annual Global Investment Conference. CEO George Achilleos will deliver a virtual corporate presentation available on-demand starting September 11, 2026 at 7:00 a.m. ET, covering commercial, clinical, regulatory progress and the NetraAI platform.
NetraMark senior management will also hold in-person, one-on-one investor meetings at the Lotte New York Palace Hotel in New York City on September 14–15, 2026. Interested parties can access the online presentation via the provided presentation link, and learn more at www.netramark.com.
NetraMark (OTCQB: AINMF)/b) reported a sharp expansion in its commercial activity for fiscal 2026, driven by its NetraAI clinical-trial analytics platform. The company entered fiscal 2026 with approximately C$322,000 in booked contract value and has added about C$3.415 million in new contracts, lifting total booked contract value available for execution in 2026 and future periods to roughly C$3.737 million. New contracts are up about 645% versus the prior annual high of C$458,000. For the first nine months of fiscal 2026, NetraMark recognized revenue of C$559,564, up about 45% from C$386,085 a year earlier, with about C$3.18 million of booked value still unrecognized. Operational highlights include a new late-stage biopharmaceutical engagement, the first commercial project through a CRO partner, appointment of a fractional Chief Medical Officer, growing CRO bid activity, and continued scientific and regulatory-focused research across psychiatry, neurodegeneration and oncology.
NetraMark (OTCQB: AINMF) has engaged AM Public Relations, a healthcare-focused communications agency, to support its strategic communications and market awareness. The collaboration is intended to help communicate NetraMark’s clinical development initiatives, its proprietary NetraAI platform, and broader scientific and commercial progress.
According to NetraMark, AM PR will assist in reaching key audiences such as investors, potential partners, industry stakeholders, and the healthcare community by translating complex clinical trial and AI technology concepts into clear narratives that highlight NetraAI’s role in generating insights from clinical trial data and in explainable AI for drug development.
NetraMark (OTCQB: AINMF) signed a new contract to analyze a phase 2 neurodegeneration clinical trial dataset through its contract research organization (CRO) partner, marking its first engagement routed via a CRO.
The project uses the proprietary NetraAI platform to identify explainable Model-Derived Subgroups and treatment-response patterns in central nervous system (CNS) disorders, aiming to support patient stratification, trial design, and future drug-development decisions.
NetraMark (OTCQB: AINMF) signed a new NetraAI clinical trial analysis agreement with a biopharmaceutical company developing a late-stage central nervous system therapy. This is NetraMark’s ninth commercial contract since October 2025, highlighting growing use of its AI platform in late-stage clinical development.
NetraAI will analyze patient-level data from a completed mid-to-late-stage trial, generating insights on dose response, efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns, and patient stratification to support the client’s late-stage program decisions.
NetraMark (OTCQB: AINMF) will deliver a corporate presentation at the virtual Sidoti Small Cap Conference on June 18, 2026, at 9:15 a.m. ET. Senior management will discuss commercial, clinical, and regulatory progress for NetraAI, its proprietary AI platform for pharmaceutical clinical trials.
NetraMark will also hold one-on-one virtual meetings on June 17–18, 2026.
NetraMark (OTCQB: AINMF) will participate in the American Society of Clinical Psychopharmacology Annual Meeting in Miami from May 26–29, 2026. Founder Dr. Joseph Geraci joins a plenary on AI in psychiatry, and the company presents two posters on explainable AI–driven precision psychiatry using its NetraAI platform.
NetraMark (OTCQB: AINMF) reported a second quarter 2026 update, emphasizing commercial, scientific, regulatory and capital markets progress for its NetraAI clinical trial analytics platform.
Key items include a Cdn$3.5M private placement, TSX uplisting, new pharma contracts, growing proposals, and a Cdn$2.96M revenue backlog.
NetraMark (OTCQB: AINMF) appointed Dr. Panteli Theocharous as Fractional Chief Medical Officer on May 4, 2026, to support global deployment of the NetraAI platform. Dr. Theocharous will continue his roles at Worldwide Clinical Trials and will advise on clinical strategy, trial design, patient stratification, and regulatory translation. Outgoing CMO Dr. Larry Alphs will remain as an advisor to ensure continuity.